Heterocyclic pericondensed CDC7 kinase inhibitors for the treatment of cancer

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is a 5-10 membered heteroaryl, optionally substituted with 1-3 substituents independently selected from the group consisting of C1-C6 alkyl, amino, halogen, hydroxy, cyano, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl;
• Y is —S— or —S(═O)—;
• Ring A is a C5-C7 cycloalkyl or 5-7 membered heterocyclyl;
• each R2 is independently selected from the group consisting of hydrogen, halogen, hydroxy, cyano, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, —NRBRC, C1-C6 alkoxyalkyl, —C(═O) NH-5-10 membered heteroaryl, 4-6 membered heterocyclyl, 5-10 membered heteroaryl, C1-C6 alkyl optionally substituted with 1-3 independently selected RA, and C3-C6 cycloalkyl optionally substituted with hydroxyl;
• or
• two R2 together with the atom to which they are attached, join together to form an oxo group;
• a C3-C6 cycloalkyl optionally substituted with 1-3 substituents independently selected from halogen, cyano, C1-C6 alkyl, and C1-C6 alkoxy;
• or a 3-6 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from halogen, cyano, C1-C6 alkyl, and C1-C6 alkoxy;
• R3 is selected from hydrogen and C0-C6 alkyl optionally substituted with 1-4 substituents independently selected from:
• (i) hydroxyl;
• (ii) cyano;
• (iii) halogen;
• (iv) C3-C6 cycloalkoxy;
• (v) C(═O) ORF;
• (vi) C1-C6 alkoxy;
• (vii) 4-10 membered heterocyclyloxy optionally substituted with 1-3 independently selected halogens;
• (viii) —NRBRC;
• (ix) C3-C6 cycloalkyl optionally substituted with 1-3 groups independently selected from hydroxyl, cyano, halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, —NRBRC, 3-6 membered heterocyclyloxy, and 3-6 membered heterocyclyl optionally substituted with 1-3 C1-C6 alkoxy;
• (x) 3 to 10 membered heterocyclyl optionally substituted with 1-4 substituents independently selected from halogen, hydroxyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6 haloalkyl, —NRBRC, C1-C6 alkyl optionally substituted with 1-3 substituents independently selected from halogen, C1-C6 alkoxy, and C3-C6 cycloalkoxy, and C3-C6 cycloalkyl optionally substituted with halogen or hydroxyl;
• (xi) 5-6 membered heteroaryl optionally substituted with 1-3 substituents independently selected from cyano, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, and 4-10 membered heterocyclyl, wherein said C3-C6 cycloalkyl is optionally substituted with 1-2 substituents independently selected from cyano and hydroxyl, and said 4-10 membered heterocyclyl is optionally substituted with 1-3 independently selected RA;
• and
• (xii) —C(═O)—X;
• wherein X is —NRBRC, C1-C6 alkyl, 5-6 membered heteroaryl, —NH-5-6 membered heteroaryl, —ORE, or 3-6 membered heterocyclyl optionally substituted with hydroxyl;
• each RA and RE are independently halogen, cyano, hydroxyl, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkylamino, 4-6 membered heterocyclyl, or C3-C6 cycloalkyl;
• each RB and RC are independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, —C(═O)—C1-C6 alkyl, —(C1-C6 alkylene)p-C3-C8 cycloalkyl optionally substituted with C1-C6 alkyl, cyano, halogen, hydroxyl, or C3-C6 cycloalkyl;
• 3 to 6 membered heterocyclyl optionally substituted with C1-C6 alkyl;
• —C(═O)O—C1-C6 alkyl;
• or benzyl optionally substituted with C1-C6 alkoxy;
• or
• RB and RC together with the atom to which they are attached, join together to form a 4-10 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from halogen, hydroxyl, cyano, C1-C6 alkyl, —NRFRG, C3-C6 cycloalkoxy, C1-C6 haloalkoxy, and C1-C6 alkoxy;
• each p is independently 0 or 1;
• m is 0, 1, 2, 3, or 4;
• R4 is hydrogen or C1-C6 alkyl;
• and
• each RF and RG are independently hydrogen or C1-C6 alkyl.